IPM Take
The emergence of ophthalmic safety questions around semaglutide highlights an important principle of personalised medicine: clinical success cannot be measured solely by metabolic outcomes. While semaglutide delivers substantial benefits for many patients with diabetes and obesity, individuals with existing diabetic eye disease may require closer monitoring during treatment initiation. The future challenge is not limiting access to effective therapies but ensuring risk-adapted care pathways that integrate endocrinology, primary care and ophthalmology.
Executive Summary
Semaglutide-based therapies, including Ozempic, Wegovy and Rybelsus, have become important tools for managing type 2 diabetes and obesity. By improving blood sugar control and supporting weight loss, these medicines can reduce long-term complications associated with diabetes. However, ophthalmologists are increasingly assessing reports of temporary blurred vision, worsening diabetic retinopathy and possible associations with non-arteritic anterior ischemic optic neuropathy (NAION). Current evidence does not demonstrate a causal relationship between semaglutide and severe vision loss, but experts recommend vigilance, particularly among patients with pre-existing diabetic retinopathy. As GLP-1 therapies become more widely used, integrated monitoring strategies may help maximise treatment benefits while protecting vision.
Why it matters
- Clinicians: Patients with diabetes who begin semaglutide therapy may require closer ophthalmic follow-up, particularly when diabetic retinopathy is already present.
- Hospitals and providers: Greater coordination between endocrinology, primary care and ophthalmology may be needed as use of GLP-1 therapies expands.
- Patients and advocates: Awareness of potential visual symptoms can support earlier reporting, timely intervention and better long-term outcomes.
Semaglutide therapies have rapidly become one of the most significant developments in diabetes and obesity management.
Marketed under brand names including Ozempic, Wegovy and Rybelsus, these GLP-1 receptor agonists have demonstrated substantial benefits in controlling blood glucose levels and supporting weight loss. For many patients, these improvements translate into lower risks of cardiovascular disease, kidney complications and other consequences of poorly controlled diabetes.
However, as the use of semaglutide continues to expand globally, ophthalmologists are paying increasing attention to its potential effects on vision and eye health.
Why vision can change
The connection between semaglutide and vision is largely linked to the body’s response to changing blood sugar levels.
Semaglutide stimulates insulin production, reduces glucose production in the liver and helps regulate appetite. As blood sugar levels improve, temporary changes may occur within the eye’s natural lens.
These shifts can alter how light is focused onto the retina, leading to blurred vision during the first months of treatment. Experts note that this effect is generally temporary and tends to resolve as glucose levels stabilise.
Older adults may experience more noticeable symptoms because the lens naturally becomes less flexible with age, making adaptation slower.
Although these visual changes can be unsettling, they are usually reversible and do not indicate permanent damage.
The diabetic retinopathy challenge
A more important concern relates to diabetic retinopathy, one of the leading causes of vision loss among working-age adults.
Diabetic retinopathy develops when elevated blood sugar damages retinal blood vessels, leading to leakage, bleeding and progressive retinal injury.
Paradoxically, rapid improvements in blood sugar control can sometimes temporarily worsen diabetic retinopathy before longer-term benefits become apparent. This phenomenon has been observed with intensive glucose-lowering strategies and is not unique to semaglutide.
For most patients, this does not result in significant complications. However, individuals with existing diabetic retinopathy may require more frequent retinal monitoring during the early stages of treatment.
The finding reinforces a core principle of personalised medicine: patients with different baseline risks may require different monitoring approaches, even when receiving the same therapy.
Questions around optic nerve health
Researchers are also investigating whether semaglutide could be associated with an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a condition caused by reduced blood flow to the optic nerve.
NAION can result in sudden vision loss and is already known to occur more frequently in people with diabetes and other vascular risk factors.
While some observational studies have suggested a potential association, experts caution that current evidence is insufficient to establish causation.
Further research will be necessary to determine whether semaglutide itself contributes to risk or whether observed cases reflect the underlying characteristics of the populations receiving treatment.
At present, specialists generally recommend awareness and monitoring rather than changes to prescribing practice.
The importance of integrated care
The growing use of GLP-1 therapies illustrates the increasingly interconnected nature of chronic disease management.
A patient receiving semaglutide may be managed simultaneously by a primary care physician, endocrinologist, cardiologist and ophthalmologist. Effective communication across these disciplines can help identify visual symptoms early and ensure appropriate follow-up.
Routine eye examinations remain essential for people living with diabetes, regardless of treatment strategy.
For patients with established retinal disease, ophthalmic monitoring may become particularly important during periods of rapid metabolic improvement.
Looking ahead
Several important studies are underway to better understand the long-term ophthalmic effects of semaglutide.
Among them is the FOCUS study, which is evaluating the impact of semaglutide on diabetic retinopathy progression in people with type 2 diabetes. The results are expected to provide greater clarity regarding risk profiles and monitoring requirements.
For now, the overall evidence continues to support semaglutide as an effective treatment option for many patients.
The challenge for personalised medicine is ensuring that therapeutic benefits are accompanied by risk-adapted monitoring strategies capable of protecting vision while improving metabolic health.
As diabetes care becomes increasingly personalised, ophthalmology will play an important role in ensuring that better glucose control translates into better patient outcomes across the entire care pathway.
